Pulmed
Latest round
- Series C
Last raised
- Jan 2022
Total raised
- $41M
Investors
- 7
About Pulmed
Based in Hangzhou, China and established in 2015, Pulmed is a clinical-stage biotechnology company that focuses on discovering, developing, and commercializing transformative inhalation therapies for respiratory diseases. In 2019, it completed a pilot BE study for CXF11. In 2020, it completed pivotal BE study for CXF11. In 2021, it completed a license in deal with Aerami Therapeutics for PAH treatment and the company selected as a quasi-unicorn enterprise in Hangzhou. The company provides inhalation products based on two proprietary technology platforms covering powder formulation and inhaler design. The formulation platform used micronization and blending technology and state of art engineered particle formation technology to reach most optimal lung deposition. The device platform with less inhalation flow dependent, and smart with digital communication function, use energy from users' inhalation optimally to disperse bulk powder and to deliver particles to the lung. The company plans to develop innovative inhaled drug delivery products, external commercial cooperation and the construction of new production bases.
Who invested in Pulmed
7 investors across 4 rounds
See all investors in Pulmed
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Pulmed
Who invested in Pulmed?
Pulmed has 7 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Pulmed raised?
Pulmed has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Pulmed last raise money?
Pulmed's most recent round on record is a Series C, in Jan 2022.
What does Pulmed do?
Based in Hangzhou, China and established in 2015, Pulmed is a clinical-stage biotechnology company that focuses on discovering, developing, and commercializing transformative inhalation therapies for respiratory diseases.
Where is Pulmed headquartered?
Pulmed is headquartered in Hangzhou, China.
Which VCs invest in companies like Pulmed?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at Pulmed's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like Pulmed? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.